NCT02632916View on ClinicalTrials.gov

Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

February 3, 2020

Study Completion Date

February 3, 2020

Conditions
Osteoporosis
Interventions
DRUG

Zoledronic Acid

Intravenous zoledronic acid 0.025mg/kg at baseline, 6 months, 12 months and 18 months

DRUG

Denosumab

Subcutaneous denosumab 1.0mg/kg at baseline, 6 months, 12 months and 18 months

Trial Locations (1)

K1H 8L1

Children's Hospital of Eastern Ontario, Ottawa

All Listed Sponsors
lead

Children's Hospital of Eastern Ontario

OTHER

NCT02632916 - Denosumab for the Treatment of Osteoporosis in Children: A Pilot Study | Biotech Hunter | Biotech Hunter